Argenx

Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Azafaros

Secures € 132M in Oversubscribed Series B Financing to advance Phase 3 clinical programs of innovative therapies in lysosomal storage disorders

AbolerIS Pharma

Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

AbolerIS Pharma

Announces Formation of Scientific Advisory Board

Augustine Therapeutics

raises oversubscribed EUR 78 million / USD 85 million Series A financing round